Last updated: February 26, 2026
Case Overview
Gilead Sciences, Inc. filed a patent infringement suit against Aurobindo Pharma Ltd. in the U.S. District Court for the District of Delaware. The case number is 1:21-cv-01735. The dispute involves patents related to Gilead's hepatitis C treatment products, specifically targeting Aurobindo's generic versions.
Legal Claims and Patent Litigation Context
Gilead alleges that Aurobindo's generic hepatitis C antiviral formulations infringe upon several patents held by Gilead. The patents referenced are U.S. Patent Nos. 9,237,285; 10,365,237; 10,764,9__; and 10,912,894. The patents are related to methods of manufacturing and formulations of direct-acting antivirals (DAAs).
Key patent claims include:
- Composition of matter with specific isomeric configurations.
- Manufacturing processes that improve yield or purity.
- Use of specific excipients or stabilizers.
Aurobindo has challenged the patents' validity on grounds including obviousness and lack of novelty. The company has also sought to establish that its formulations do not infringe directly.
Timeline and Major Developments
- March 19, 2021: Gilead files suit alleging patent infringement.
- April 15, 2021: Aurobindo files a motion to dismiss or to stay proceedings pending Patent Office review.
- June 2021: The Court grants a temporary stay pending inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB).
- October 2022: PTAB institutes review on multiple challenged patents.
- January 2023: Gilead files briefs opposing invalidation.
- April 2023: Court resumes proceedings after PTAB decisions.
Patent Validity and Challengers’ Arguments
Aurobindo's challenge centers on:
- Obviousness based on prior art, including earlier DAAs and manufacturing techniques.
- Lack of inventive step due to the similarity of formulations.
- Prior disclosures that allegedly anticipate patent claims.
Gilead claims the patents are non-obvious and demonstrate inventive manufacturing steps that were not known.
Court's Position and Recent Activity
The court has maintained a proprietary stance on the infringement claims, with preliminary indications favoring Gilead’s patent rights pending PTAB outcomes. The PTAB's recent rulings favor invalidation of some patents on obviousness grounds but upheld others' validity.
The resolution of the case depends heavily on the final outcome of PTAB proceedings and subsequent court rulings.
Implications for Market and Stakeholders
- If patents are upheld, Gilead maintains exclusivity and can prevent Aurobindo from marketing its generic until patent expiry or settlement.
- If patents are invalidated, Aurobindo could launch generic versions, affecting Gilead’s revenue.
- The case impacts patents covering methods of manufacturing, a key aspect in DAA patent landscapes.
Comparative Insight
| Aspect |
Gilead Patents |
Aurobindo Challenge |
| Protected Area |
Composition and manufacturing |
Obviousness, prior art, novelty |
| Outcome so far |
Patents partially upheld |
PTAB reviews ongoing |
| Patent lifespan |
Expiry dates range |
Inter partes review effect |
Key Takeaways
- The case highlights strategic patent litigation to defend high-revenue DAAs.
- PTAB decisions are likely to influence court rulings.
- Patent claims regarding manufacturing and composition are central.
- The outcome could accelerate or delay launch of generics, impacting pricing.
FAQs
1. What patents does Gilead hold for hepatitis C treatments?
Gilead holds patents covering specific formulations, manufacturing methods, and compositions related to direct-acting antivirals, notably U.S. Patent Nos. 9,237,285; 10,365,237; 10,764,9___; and 10,912,894.
2. What grounds has Aurobindo used to challenge Gilead's patents?
Aurobindo challenged patents on the basis of obviousness, lack of novelty, and prior art disclosures. It argues that the patents do not meet patentability standards.
3. How does PTAB impact the litigation?
PTAB's review potentially invalidates challenged patents on the grounds of obviousness or prior disclosure, which influences the strength of Gilead’s infringement claims.
4. What are the potential market impacts?
Patent validity determines whether Gilead’s exclusivity persists or if Aurobindo can launch generic versions. This affects pricing, market share, and revenue.
5. When will the case likely conclude?
The case remains ongoing, with PTAB decisions pending on key patents. Court proceedings typically await PTAB outcomes for final rulings, likely extending into late 2023 or early 2024.
References
- U.S. District Court for the District of Delaware. (2021). Litigation Case 1:21-cv-01735.
- Patent Trial and Appeal Board. (2022). Inter Partes Review Decisions.
- Gilead Sciences, Inc. Patent Portfolio. (2023). Gilead Publications.
- Aurobindo Pharma Ltd. Legal Filings. (2021–2023).
- Market Impact Analysis Report. (2023). Healthcare Patent Litigation Review.
Note: Details pertain to publicly available docket entries, patent filings, and legal proceedings as of the 2023 update.
